本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Viking Therapeutics, Inc.

32.07
+0.44001.39%
盤後32.05-0.0200-0.06%19:58 EDT
成交量:322.96萬
成交額:1.04億
市值:36.02億
市盈率:-27.81
高:32.75
開:32.20
低:31.92
收:31.63
資料載入中...
2025/07/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/07/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/07/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/05/27

重要事件披露

Form 8-K - Current report
2025/04/24

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/23

重要事件披露

Form 8-K - Current report
2025/04/09

SEC問詢函

Form CORRESP - Correspondence
2025/03/11

重要事件披露

Form 8-K - Current report
2025/02/26

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/05

重要事件披露

Form 8-K - Current report
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 擬減持2000股,總價約13.73萬美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

關聯方擬減持公告

Form 144 | Viking Therapeutics高管Greg Zante擬減持131687股,總價約1028萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 擬減持11000股,總價約88.94萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Singleton擬減持16000股,總價約127萬美元